Efficacy and Safety of Targeted Immunotherapy with ANX005 in Treating Guillain-Barré Syndrome: A Phase 3 Multicenter Study (PL5.006)
Evaluate the efficacy and safety of ANX005 compared to placebo in Guillain-Barré syndrome (GBS) patients.
Authors
- Ted Yednock (ORCID: https://orcid.org/0000-0002-9637-8555)
- Ping Lin (ORCID: https://orcid.org/0000-0002-0641-6440)
- Glenn Morrison
- Jose C. Navarro (ORCID: https://orcid.org/0000-0003-3204-4123)
- Peter J. Collins (ORCID: https://orcid.org/0000-0003-4478-3644)
- Henk‐André Kroon
- Benjamin Hoehn
- Eric Humphriss
- Quazi Deen Mohammad (ORCID: https://orcid.org/0000-0001-6009-0536)
- Zhahirul Islam (ORCID: https://orcid.org/0000-0003-0935-8079)
- Dean R. Artis
- Khan Abul Kalam Azad
Institutions
- Annexon Biosciences (United States) (US)
- José R. Reyes Memorial Medical Center (PH)
- National Institute of Neurosciences & Hospital (BD)
- Dhaka Medical College and Hospital (BD)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212033
- Citations
- 7
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 9.72